Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

indolidan

Known as: 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one 
 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

IndolesPyridazines

Narrower (1)

LY 195115

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
1996
Highly Cited
1996
cAMP-mediated vascular protection in an orthotopic rat lung transplant model. Insights into the mechanism of action of prostaglandin E1 to improve lung preservation.
Prostaglandin E1 (PGE1) is often added to the donor pulmonary flush solution to enhance clinical lung preservation for… Expand
Highly Cited
1995
Highly Cited
1995
cGMP and nitric oxide modulate thrombin-induced endothelial permeability. Regulation via different pathways in human aortic and umbilical vein endothelial cells.
Previous studies have demonstrated that cGMP and cAMP reduce the endothelial permeability for fluids and macromolecules when the… Expand
1995
1995
Mitogenic and antimitogenic effects of pituitary adenylate cyclase-activating polypeptide (PACAP) in adult rat chromaffin cell cultures
The neurotransmitter, pituitary adenylate cyclase-activating polypeptide (PACAP), is present in the rat adrenal medulla and is a… Expand
Highly Cited
1993
Highly Cited
1993
Characterization of indolidan- and rolipram-sensitive cyclic nucleotide phosphodiesterases in canine and human cardiac microsomal fractions.
The distribution of phosphodiesterase (PDE) activities was studied in canine cardiac microsomal fractions separated by sucrose… Expand
1991
1991
Selective inhibition of cGMP-inhibitable cAMP phosphodiesterase decreases pulmonary vasoreactivity.
Guanosine 3',5'-cyclic monophosphate (cGMP) and adenosine 3',5'-cyclic monophosphate (cAMP) are mediators of smooth muscle… Expand
1991
1991
Cardiovascular and adrenal proliferative lesions in Fischer 344 rats induced by long-term treatment with type III phosphodiesterase inhibitors (positive inotropic agents), isomazole and indolidan.
Male and female Fischer 344 rats were treated with the positive inotropic agents, isomazole or indolidan, in the diet for 104… Expand
1990
1990
Regulation of calcium current by low-Km cyclic AMP phosphodiesterases in cardiac cells.
The voltage-gated Ca2+ current (ICa) in cardiac myocytes is regulated by cAMP-dependent phosphorylation. Although the regulation… Expand
1989
1989
Specific binding of [3H]LY186126, an analogue of indolidan (LY195115), to cardiac membranes enriched in sarcoplasmic reticulum vesicles.
LY186126 was found to be a potent inhibitor of type IV cyclic AMP phosphodiesterase located in the sarcoplasmic reticulum of… Expand
  • figure 1
  • figure 2
  • table 1
1989
1989
Synthesis of a tritium-labeled indolidan analogue and its use as a radioligand for phosphodiesterase-inhibitor cardiotonic binding sites.
We have radiolabeled a structural analogue of indolidan, a potent phosphodiesterase-inhibitor cardiotonic, to permit biochemical… Expand
1989
1989
Nonsteroidal cardiotonics. 2. The inotropic activity of linear, tricyclic 5-6-5 fused heterocycles.
We previously reported the structure-activity relationships (SAR) of adibendan (1), a potent and long-acting cardiotonic. This… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE